If you took a position just on NASDAQ listing, you have done just fine. 28c to 50c is mighty nice in anyone's books for a 3 month period. 100% return if you sold few weeks back actually.
But I would hope that in that 3 months you would have researched the company to show that at US $400million market cap we are multiples from peer comparison.
Just taking IHL-675A in Rheumatoid Arthritis (not counting the COPD, ARDS or IBS targets but as a direct substitute for existing RA treatment of HCQ tablet Plaquenil which is still growing at a CAGR of 5.3% according to this prior research, then we already warrent a higher valuation based on whatever future discount cash flows or market penetrative model you care to use.
https://www.globenewswire.com/en/news-release/2020/06/15/2048190/0/en/Global-Hydroxychloroquine-Market-is-estimated-to-be-US-2-7-Billion-by-2029-with-a-CAGR-of-5-3-during-the-Forecast-Period-PMI.html
